SiPhox Targets $70B Wearable Health Market With Five Hires

How SiPhox Filters Candidates

SiPhox Health lists five open roles spanning consumer experience, product management, software leadership, operations, and technical product, as it pushes to move its silicon photonic blood-testing platform from mail-in kits to a fully at-home device by 2026. Interview guides published in April 2025 show a concentration on data structures and algorithms (80 questions across two SiPhox guides), machine learning (48), SQL (28), and statistics (15). Glassdoor hosts five anonymous interview reviews and five questions. The company's own description, "silicon photonics, microfluidics, embedded systems, and semiconductor-grade manufacturing," signals that software candidates need literacy in hardware constraints: timing budgets, signal-to-noise trade-offs, yield-aware design.

Five Open Roles, One Direction

SiPhox Health lists five open positions on its Y Combinator company page, each tied to a distinct piece of the push toward at-home diagnostic scale. The roles cluster around product, operations, and software leadership, reflecting a team of 63 (per Y Combinator) that is shifting from R&D into commercial execution. All five postings specify years-of-experience minimums and, in most cases, a concise ownership mandate.

Head of Consumer Experience; Home Blood Testing
Listed on Y Combinator, this role asks for six-plus years of experience. Location: Boston, with a Remote (US) option. The title signals ownership of the end-to-end consumer journey, from kit unboxing to results delivery, for a product that already ships a $150 mail-in blood testing kit and returns results in a week (Boston Globe).

Product Manager, Mail-In Blood Testing
Active on jobs.product.jobs and Y Combinator, this Boston-based role requires three-plus years of experience. The posting states the mandate explicitly: "Own end-to-end product lifecycle for mail-in blood testing from kit to results." That scope covers logistics, lab coordination, regulatory touchpoints, and the consumer-facing results interface.

Full-Stack Software Development Lead
Listed on Y Combinator as Remote, this role requires six-plus years of experience. The compensation band is notably lower than the product-leadership roles. The company's silicon-photonic readout and forthcoming at-home device (targeted for 2026 per the Boston Globe) imply embedded firmware, cloud data pipelines, and a consumer mobile app.

Wartime Operations and Product Lead
Posted there, this Boston role requires three-plus years. The description reads: "Own the end-to-end operations and product roadmap for at-home test kits." The "wartime" label signals a mandate to resolve supply-chain, manufacturing, and fulfillment bottlenecks as the company moves from the kits to a fully at-home platform by 2026.

Technical Product Manager
The oldest posting, active there, this Boston role has the lowest experience floor at one-plus years. The mandate: "Own end-to-end product roadmap for the wearable at-home health monitoring platform." The "technical" qualifier and the wearable-platform scope point to a candidate who can translate silicon-photonic chip specifications, microfluidic cartridge design, and biomarker panel expansion into engineering tickets.

Across all five roles, the stated requirements converge on three themes: explicit ownership language ("own end-to-end"), a Boston hub with selective remote flexibility, and experience floors that range from one to six years.

The Hidden Criteria

The Technical Product Manager listing on alion.io makes the operating tempo explicit. It asks for a "10x Builder" who is an "AI-native developer / vibe-coding power user" constantly experimenting with the latest LLMs to ship production-grade code at pace. The same posting demands prototypes in hours, not weeks, and "Extreme Ownership" across design, implementation, testing, observability, and production testing. That language reflects a team that moved from MIT lab to Y Combinator to a Series A led by Intel Capital, and now runs a manufacturing facility in Burlington.

Silicon photonics engineers face a parallel bar. Industry qualification guides cite Lumerical, COMSOL, and cleanroom process familiarity, plus emerging JEDEC reliability standards and OIF Energy Efficient Interfaces – Compute Optics Interface (EEI-COI) specifications. SiPhox's chip is not a research device; it is a sub-millimeter photonic circuit board meant to replace refrigerator-sized diagnostic instruments and ship to homes (MIT News).

Clinical translation is another requirement. The product must turn raw optical signals into 17 to 60 biomarker readings that a consumer understands and a physician trusts. The TPM role calls for "Product Instinct: A proven track record of shipping software that isn't just functional, but intuitive. You can translate complex clinical data into a clean, actionable user experience." That instinct is tested against a regulatory landscape where the chip-based device is not yet FDA-cleared; it operates as a wellness-tier tool via CLIA-certified lab partners, while the company prepares clearance studies (MIT News, BioSpace).

Cross-disciplinary fluency rounds out the criteria. The founding team, Michael Dubrovsky and Diedrik Vermeulen, met at MIT across the Silicon Photonics Group and the Materials for Micro and Nano Systems group, then bonded over a printed-circuit-board approach to optical chips (MIT News). The Series A explicitly funded expansion across biology, science, engineering, and mechanical engineering simultaneously (TechCrunch).

Inside the Company

SiPhox Health began as a bet that the silicon photonics revolution that reshaped internet infrastructure could do the same for blood diagnostics. The company was founded in 2020 by two MIT researchers — Diedrik Vermeulen, who helped develop the first coherent silicon photonic transceiver chip now used globally in data centers, and Michael Dubrovsky, whose background sits at the intersection of biomedical engineering and photonics (MIT News, TechCrunch). They entered the Y Combinator summer cohort that same year, working from Burlington, Massachusetts.

The core insight was straightforward: traditional lab blood analyzers weigh hundreds of pounds and cost half a million dollars because they rely on bulky free-space optics (StartupIntros). Vermeulen and Dubrovsky miniaturized those same optical components (lenses, polarizers, modulators, splitters) onto a 1-millimeter silicon chip manufactured in standard semiconductor fabs (MIT News). A single fab, they calculate, could produce 1 billion chips per month (MIT News). Each disposable cartridge contains an array of photonic immunoassay sensors that detect specific proteins or hormones from a finger-prick sample, delivering results in under five minutes (MIT News, TechCrunch). The device itself is roughly the size of a coffee maker and weighs about one pound (Boston Globe, StartupIntros).

"We don't change any of the main features. We leave all the optics the same, but we miniaturize it onto our chips and make it so scalable that you can ship it to homes," Vermeulen said in a November 2024 MIT News interview. "It's like how computers used to be the size of a room — now they're all on a chip. We're doing the same for blood testing."

The funding trajectory reflects investor conviction. A seed round co-led by Khosla Ventures and Y Combinator brought in Metaplanet, the Massachusetts Manufacturing Innovation Initiative, and individual backers including Paul Buchheit, Balaji Srinivasan, and Bob Lee (TechCrunch). In July 2023, Intel Capital led a $17 million Series A with participation from Khosla Ventures, Kortex Ventures, Alumni Ventures, Metaplanet, Shorewind Capital, LongeVC, Overlap Holdings, and Duke Capital Partners — bringing total capital raised to roughly $32 million (TechCrunch, Tracxn, TheCompanyCheck). The Series A explicitly targeted team expansion across those fields (TechCrunch).

Headcount tells the growth story. The company reported approximately 25 employees as of June 2024, reaching $5 million in annual revenue that same month (GetLatka). By August 2026, Tracxn tracked 80 employees — more than a threefold increase in roughly two years. Leadership includes Vermeulen as CEO, Dubrovsky as CPO and co-founder, Pavel Korecky as Director of Product Operations, Anthony Dias as CFO, and software engineer Mykhailo Halaida among the technical core (TheCompanyCheck).

The hiring surge maps to three converging imperatives. First, FDA clearance. The at-home device remains investigational; the company has been running mail-in tests using conventional lab technology while validating its photonic system against central lab methods (MIT News, TechCrunch, SiPhox tech page). MIT News reported in November 2024 that the Burlington facility can manufacture about 10,000 cartridges per month, and third-party validation of accuracy is complete. The next step is the pivotal clinical study, a "case study on this with thousands of people," as Dubrovsky said in a 2023 TechCrunch interview, which demands regulatory, quality, and clinical operations hires.

Second, test menu expansion. The current platform covers up to 20 biomarkers per cartridge across cardiovascular, metabolic, inflammatory, and hormonal panels (MIT News). The roadmap includes thyroid, sex hormones, cardiac markers, and cancer screening panels — each requiring new assay development, surface chemistry optimization, and validation work (SiPhox technology page).

Third, platform integration. The company's dashboard already ingests third-party lab PDFs via large language models, syncs with Apple Watch, Oura Ring, and Fitbit, and offers an AI health assistant called Sai (Fitt Insider, SiPhox website).

Competitive pressure sharpens the urgency. Tracxn lists 53 active competitors in at-home health testing, with 11 funded. Function Health, Everlywell, and LetsGetChecked lead the pack; SiPhox ranks ninth (Tracxn). Few rivals own the photonics stack; most rely on centralized lab processing with multi-day turnaround (Biohacker Atlas). SiPhox's differentiator, lab-grade results from a countertop device in minutes, only matters if they clear FDA and manufacture at scale.

Building a Winning Application

SiPhox Health's screening rewards candidates who can prove they've already solved problems that look like the ones sitting on the team's bench. The company's core challenge, shrinking a clinical lab onto a silicon photonic chip that sits on a nightstand, sits at the intersection of photonics, microfluidics, assay chemistry, and machine learning.

Start with the photonics foundation. The Boston Globe described SiPhox's forthcoming device as "a Mr. Coffee machine" that "runs on blood" and "uses laser light and microchips to identify dozens of medical biomarkers." That description maps to the skill set the screening filters for: waveguide design, on-chip spectroscopy, and the packaging challenges when biological fluids meet semiconductor processes. If your background includes designing silicon nitride or silicon-on-insulator circuits for biosensing, not just telecom, lead with that.

Next, demonstrate fluency in the assay-to-algorithm loop. SiPhox's dashboard "tracks trends, flags changes and translates data into next steps, from lifestyle shifts to supplement recommendations," per USA Today coverage. That pipeline (raw spectral data → biomarker concentration → longitudinal trend → clinical insight) is where the AI-driven diagnostics requirement lives. Candidates who have built models on noisy, low-volume biological data should quantify the signal-to-noise ratios they worked with and the false-positive rates they drove down. Experience with CLIA-certified lab workflows is a signal; mention the specific assays you validated and the regulatory pathway you navigated.

The EasyDraw collection device adds a mechanical constraint. "The process takes about five minutes, no traditional needles are involved," the New York Post noted. That upper-arm microsampling system implies expertise in fluidic path design, surface chemistry for capillary action, and user-centered industrial design. If you've taken a fluidic cartridge from CAD to molded production, describe the yield loss you diagnosed and the design change that recovered it.

The Samsung partnership announced at VivaTech 2026 reveals where the product roadmap is heading: integration into a consumer ecosystem with 460 million SmartThings users and 77 million Samsung Health users (TechBuzz). That scale demands engineers who have built cloud infrastructure for regulated health data — HIPAA-compliant pipelines, FHIR interoperability, and observability stacks that catch drift before a biomarker trend becomes a clinical liability.

For the GLP-1 Monitor role, the Daily Beast highlighted tracking "body recomposition trends, nutritional health, and common medication-related side effects." Show you understand the biomarker panel (testosterone, SHBG, cortisol, ferritin, lipid fractions) and why each matters for the GLP-1 population.

Tailor your application materials to the company's current inflection point. Five years in, SiPhox has moved from Y Combinator demo to a shipping $99 kit with 60 biomarkers, but the silicon photonic "lab on chip" remains pre-commercial per a 2023 Reddit technical breakdown noting the company used a white-label lab partner (Spot). The hiring push signals the transition from white-label lab partner to first-party photonics manufacturing. Frame your experience as "I've built the thing you're about to scale."

Anticipate the practical assessment. Companies at this stage typically run a take-home that mirrors a real blocker: optimize a waveguide geometry for a target SNR, design a fluidic mixer for a 10 µL sample, or write the inference service that turns spectral peaks into a triglyceride reading with a confidence interval. Treat the take-home as a work sample. Document your assumptions, cite the literature you leaned on, and explain the trade-offs you'd revisit with more time.

Why This Hiring Moment Matters

SiPhox Health's five open roles arrive at a collision point between three labor markets that are each tightening. The company sits at the intersection of silicon photonics manufacturing, consumer health monitoring, and AI-driven diagnostics.

Healthcare and social assistance now account for nearly all net private-sector job growth in the United States. Deloitte's July 2026 analysis found that excluding healthcare, private payrolls averaged just 35,000 new jobs per month in 2026, while the sector itself grew real gross value added at 1.1% per quarter since 2023 — up from a 0.7% average between 2010 and 2019. The U.S. Bureau of Labor Statistics projects healthcare occupations will add roughly 2 million jobs from 2021 to 2031, a 13% growth rate far above the all-occupations average (Healthcare Readers). The World Economic Forum flags aging populations and rising chronic conditions as primary drivers; the American Association of Medical Colleges warns of a 100,000-plus physician shortfall by 2030 (Healthcare Readers).

That clinical shortage drives the wearable healthcare device market. Research cited by Healthcare Readers projects the global market for wearable healthcare devices to reach that level by 2028, creating demand for professionals skilled in data analysis and patient monitoring. SiPhox's silicon photonic platform, a lab-grade blood testing system shrunk to a consumer form factor, lands in this category. The 63% of clinicians who expect most consultations to be virtual by 2032 implies a structural shift toward remote diagnostics that devices like SiPhox's are built to enable (Healthcare Readers).

Building those devices requires a manufacturing workforce that doesn't exist at scale. Deloitte's November 2025 manufacturing outlook notes that immigrant workers filled nearly one in four U.S. manufacturing production jobs in 2024, and competition for skilled labor remains intense as manufacturers invest in advanced digital tools and smart facilities. Silicon photonics fabrication, wafer-scale integration of optical components on CMOS processes, sits at the leading edge of that push. The talent pool combines photonics design, process engineering, and semiconductor yield expertise that Talencio's August 2025 health tech workforce report identifies as among the roles where shortages are "most acute for roles that combine technical, clinical, and regulatory skillsets."

The regulatory layer compounds the squeeze. The EU AI Act and FDA's updated Quality Management System Regulation (QMSR) have pushed health tech companies to expand regulatory and quality-focused training across product, engineering, and risk management teams (Talencio). Inadequate compliance training can jeopardize market access, trigger costly audits, and expose companies to recalls — a risk profile SiPhox navigates as a Class II medical device company pursuing both FDA clearance and international expansion.

Meanwhile, the AI layer in SiPhox's stack, interpreting spectral data into clinical insights, pulls from the same machine learning engineering and clinical informatics talent that Bluesignal's May 2025 analysis shows organizations actively recruiting: ML Engineers, Data Scientists, Clinical Informatics Specialists, and Regulatory Affairs Professionals. The same report lists Biomedical Engineers, IoT Systems Architects, Clinical Data Analysts, and Cybersecurity Specialists as priority hires for Internet of Medical Things (IoMT) integration — another bucket SiPhox's connected device strategy touches (Bluesignal).

The pivotal clinical study — thousands of patients, a sub-millimeter chip, and a regulatory bar set for the living room — will decide whether SiPhox's photonics platform becomes the standard for home diagnostics or remains a promising demo. The five roles open today are the team that has to deliver it.

Working in frontier tech? Zero G Talent tracks the openings: see every open ASML role, browse frontier tech jobs, openings at Stripe, and the people building the field.